Posts Archive

CELMoD MM-002 CC-92480-MM-002 (NCT03989414) NCT03989414: A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety...

Dara-KRd NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed...

IFM2017_03 NCT03993912: Phase 3 - Lenalidomide and SC Daratumumab vs Lenalidomide and Dexamethasone in NDMM(IFM2017_03) This is a Phase...

NCT03942224: Phase 2: Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed...

The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab,...

CEPHEUS Study MMY3019 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE,...

KarMMa-3 bb2121 Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma...

Perseus Study NDMM Newly Diagnosed Multiple Myeloma EMN 17 Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to...

PLEIADES study A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimen MMY2040...

NCT03757221: Phase 2 - Ixazomib -Daratumumab Without Dex (IDara) in Elderly RRMM (IDARA) IFM 2018-02 Phase 2 Study Elderly RRMM Ixazomib...

IFM 2018-04 NCT03606577: Phase 2: An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell...

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous...

Multiple Myeloma Research Consortium MyDRUG RRMM NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG) Multiple...

Multiple Myeloma Research Consortium phase 2 study Dara-KRd NCT03500445: Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose...

NCT03589222: Phase 2: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma NCT03589222: Phase 2: SELIBORDARA:...

MANHATTAN TRIAL NCT03290950: Phase 2 - A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma Dara-KRd A Study of...

COLUMBA study A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory...

The APOLLO study EMN14/54767414MMY3013 Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed...

Phase 3 CANDOR study Dara-Kd Kd Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple...